Infections of the musculoskeletal system with chronic polyarthritis during a combination therapy with Methotrexate and Leflunomide;Infektionen des bewegungsapparates bei der chronischen polyarthritis während einer kombinationstherapie mit Methotrexat und Leflunomid

Zeitschrift fur Orthopadie und Ihre Grenzgebiete

Volumn 140, Issue 5, 2002, Pages 555-560

  Delank, Karl Stefan ^a   Hansen, T ^a   Eysel, P ^a   Eckardt, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Combination therapy; Infection; Leflunomide; Methotrexate; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION RISK; JOINT SURGERY; LUNG TOXICITY; MUSCULOSKELETAL DISEASE; POLYARTHRITIS; POSTOPERATIVE INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, INFECTIOUS; ARTHRITIS, RHEUMATOID; ARTHROPLASTY, REPLACEMENT, KNEE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; METHOTREXATE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; REOPERATION; RISK; SEPSIS; STAPHYLOCOCCAL INFECTIONS; SURGICAL WOUND INFECTION;

EID: 0036742424     PISSN: 00443220     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34005     Document Type: Article

References (31)

1. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hzeltine M, et al. Lowdose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Arthritis Rheum 1993; 36: 795-803
2. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcon GS. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 918
3. Hu SK, Mitcho YL, Oronosky AL, Kerwar SS. Studies on the effect of methotrexate on macrophage function. J Rheumatol 1998; 15: 206-209
4. Seitz M, Loetschler P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M. Methotrexate action in rheumatoid arthritis: Stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995; 34: 602-609
5. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993; 5: 298-304
6. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997; 23: 739-755
7. Chong AS, Rezai K, Gebel HM, Finnegan A, Foster P, Xu X, Williams JW. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996; 61: 140-145
8. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, Young JM, Nakano G, Ransom JT. The immunosuppressant leflunomide inhibitis lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275: 1043-1049
9. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 61: 635-641
10. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydro-orotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995; 50: 861-867
11. Tugwell P, Pincus T, Yocum D, Stein M, Gluck D, Kraag G, McKendry R, Tesser J, Baker P, Wells G. Combination therapy with cyclosporin and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporin Combination Study Group. N Engl J Med 1995; 333: 137-141
12. Stein CM, Pincus T, Yocum D, Tugwell P, Wells G, Gluck D, Kraager G, Torley H, Tesser J, McKendry R, Brooks RH. Combination treatment of severe rheumatoid arthritis with cyclosporin and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporin Combination Study Group. Arthritis Rheum 1997; 40: 1843-1851
13. O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol Suppl 1996; 44: 72-74
14. Maini RN, Breedveld FC, Kalden JR, Smolen JS, David D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563
15. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259
16. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, Strand V. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-1328
17. Furst DE, Luggen ME, Thompson AK, Coleman JO. Adding leflunomide (LEF) to patients with active rheumatoid arthritis (RA) while receiving methotrexate (MTX) improves physical function and health-related quality of life (HRQOL). Arthritis Rheum 2000; 43 (9): A 1664
18. Kremer JM, Caldwell JR, Cannon GW, Genovese M, Cush JJ, Bathon J, Coleman JC. The combination of leflunomide (LEF) and methotrexate (MTX) in patients with rheumatoid arthritis (RA) who are failing on MTX treatment alone: A double-blind placebo (PLC) controlled study. Arthritis Rheum 2000; 43 (9): A948
19. Smolen JS, Kalden JR, Rozman B, Kvien TL, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R. Efficacy and safty of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomised, multicentre trial. Lancet 1999; 353: 259-266
20. VanEde AE, Laan RF, Blom HJ, de Abreu PA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27: 277-292
21. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard J-P. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T Cells. J Clin Invest 1998; 102: 322-328
22. Menninger H. Basistherapeutische Kombinationstherapie bei chronischer Polyarthritis: Ein Überblick. Z Rheumatol 1998; 57: 25-30
23. Bridges SL, Lopez-Mendez A, Han KH, Tracy IC, Alarcon GS. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol 1991; 18: 984-988
24. Carpenter MT, West SG, Vogelsang SA, Casey Jones DE. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics 1996; 19: 207-210
25. Perhala RS, Wilke WS, Clough JD, Segal AM. Local infection complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 1991; 34: 146-152
26. Sany J, Anaya JM, Canovas F, Combe B, Jorgensen C, Saker S, Thaury MN, Gavroy JP. Infuence of methotrexate on the frequency of post-operative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993; 20: 1129-1132
27. Steuer A, Keat AC. Perioperative use of methotrexate - a survey of clinical practice in the UK. Br J Rheumatol 1997; 36: 1009-1011
28. Van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994; 53: 224-228
29. Hirshberg B, Muszkat M, Schlesinger O, Rubinow A. Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J 2000; 76: 787-789
30. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999; 10: 1366-1380
31. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospektive, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43: 1488-1495